MX2016011219A - Procedimiento para fabricar un producto de acetato de glatiramer. - Google Patents
Procedimiento para fabricar un producto de acetato de glatiramer.Info
- Publication number
- MX2016011219A MX2016011219A MX2016011219A MX2016011219A MX2016011219A MX 2016011219 A MX2016011219 A MX 2016011219A MX 2016011219 A MX2016011219 A MX 2016011219A MX 2016011219 A MX2016011219 A MX 2016011219A MX 2016011219 A MX2016011219 A MX 2016011219A
- Authority
- MX
- Mexico
- Prior art keywords
- glatiramer acetate
- mannitol
- aqueous pharmaceutical
- pharmaceutical solution
- suitable container
- Prior art date
Links
- 108010072051 Glatiramer Acetate Proteins 0.000 title abstract 5
- FHEAIOHRHQGZPC-KIWGSFCNSA-N acetic acid;(2s)-2-amino-3-(4-hydroxyphenyl)propanoic acid;(2s)-2-aminopentanedioic acid;(2s)-2-aminopropanoic acid;(2s)-2,6-diaminohexanoic acid Chemical compound CC(O)=O.C[C@H](N)C(O)=O.NCCCC[C@H](N)C(O)=O.OC(=O)[C@@H](N)CCC(O)=O.OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 FHEAIOHRHQGZPC-KIWGSFCNSA-N 0.000 title abstract 5
- 229960003776 glatiramer acetate Drugs 0.000 title abstract 5
- 238000000034 method Methods 0.000 title abstract 3
- 238000004519 manufacturing process Methods 0.000 title 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 abstract 4
- 229930195725 Mannitol Natural products 0.000 abstract 4
- 235000010355 mannitol Nutrition 0.000 abstract 4
- 239000000594 mannitol Substances 0.000 abstract 4
- 239000003186 pharmaceutical solution Substances 0.000 abstract 4
- 239000000706 filtrate Substances 0.000 abstract 2
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 2
- 238000001914 filtration Methods 0.000 abstract 1
- 229940071643 prefilled syringe Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/02—Peptides of undefined number of amino acids; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/03—Peptides having up to 20 amino acids in an undefined or only partially defined sequence; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M5/00—Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
- A61M5/178—Syringes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Immunology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Dermatology (AREA)
- Gastroenterology & Hepatology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Vascular Medicine (AREA)
- Anesthesiology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Physical Education & Sports Medicine (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
La patente proporciona un proceso de preparación de una preparación farmacéutica de acetato de glatiramer y manitol en un contenedor adecuado que comprende las etapas de: (i) obtener una solución farmacéutica acuosa de acetato de glatiramer y manitol; (ii) filtrar la solución farmacéutica acuosa a una temperatura de por encima de 0 °C hasta 17.5 °C para producir un filtrado; y (iii) llenar el contenedor adecuado con el filtrado obtenido después de realizar la etapa (ii), a fin de preparar de este modo la preparación farmacéutica de acetato de glatiramer y manitol en el contenedor adecuado. Esta patente proporciona, además, una solución farmacéutica acuosa que comprende 40 mg/ml de acetato de glatiramer y 40 mg/ml de manitol, en donde la solución farmacéutica acuosa a) tiene una viscosidad en el intervalo de 2.0 a 3.5 cPa; o b) tiene una osmolalidad en el intervalo de 275 a 325 mosmol/Kg. Esta patente también proporciona una jeringa precargada, un inyector automático y un método de tratamiento de un paciente humano.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US14/608,126 US9155775B1 (en) | 2015-01-28 | 2015-01-28 | Process for manufacturing glatiramer acetate product |
| PCT/US2015/051203 WO2016122722A1 (en) | 2015-01-28 | 2015-09-21 | Process for manufacturing glatiramer acetate product |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX2016011219A true MX2016011219A (es) | 2016-11-30 |
| MX352734B MX352734B (es) | 2017-12-06 |
Family
ID=54199060
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2016011219A MX352734B (es) | 2015-01-28 | 2015-09-21 | Procedimiento para fabricar un producto de acetato de glatiramer. |
Country Status (30)
| Country | Link |
|---|---|
| US (6) | US9155775B1 (es) |
| EP (3) | EP3113785A4 (es) |
| JP (2) | JP2018503627A (es) |
| KR (2) | KR102268210B1 (es) |
| CN (1) | CN107530394B (es) |
| AR (1) | AR102096A1 (es) |
| AU (4) | AU2015380381B2 (es) |
| BR (1) | BR112016023736A2 (es) |
| CA (2) | CA2965890A1 (es) |
| CL (1) | CL2016002607A1 (es) |
| CY (1) | CY1118826T1 (es) |
| DK (1) | DK3050556T3 (es) |
| EA (3) | EA028484B1 (es) |
| ES (1) | ES2584190T3 (es) |
| HR (1) | HRP20170625T1 (es) |
| HU (1) | HUE034059T2 (es) |
| IL (3) | IL247851A0 (es) |
| LT (1) | LT3050556T (es) |
| ME (1) | ME02721B (es) |
| MX (1) | MX352734B (es) |
| PE (1) | PE20170296A1 (es) |
| PL (1) | PL3050556T3 (es) |
| PT (1) | PT3050556T (es) |
| RS (1) | RS55959B1 (es) |
| RU (1) | RU2669769C2 (es) |
| SI (1) | SI3050556T1 (es) |
| SM (1) | SMT201700227T1 (es) |
| UA (1) | UA116060C2 (es) |
| WO (1) | WO2016122722A1 (es) |
| ZA (1) | ZA201606903B (es) |
Families Citing this family (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| USRE49251E1 (en) | 2010-01-04 | 2022-10-18 | Mapi Pharma Ltd. | Depot systems comprising glatiramer or pharmacologically acceptable salt thereof |
| US8709433B2 (en) | 2010-10-11 | 2014-04-29 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate |
| WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
| CN107550853B (zh) * | 2016-06-30 | 2020-06-12 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷注射液的制备方法 |
| US12097292B2 (en) | 2016-08-28 | 2024-09-24 | Mapi Pharma Ltd. | Process for preparing microparticles containing glatiramer acetate |
| LT3506921T (lt) | 2016-08-31 | 2023-08-10 | Mapi Pharma Ltd | Ilgesnio atpalaidavimo sistemos, kuriose yra glatiramero acetato |
| US10610104B2 (en) | 2016-12-07 | 2020-04-07 | Progenity, Inc. | Gastrointestinal tract detection methods, devices and systems |
| AU2018242998B2 (en) | 2017-03-26 | 2023-11-02 | Mapi Pharma Ltd. | Glatiramer depot systems for treating progressive forms of multiple sclerosis |
| KR102675224B1 (ko) | 2017-06-29 | 2024-06-14 | 리제너론 파아마슈티컬스, 인크. | 약물 용기를 과충진하기 위한 디바이스 및 방법 |
| WO2019036363A1 (en) | 2017-08-14 | 2019-02-21 | Progenity Inc. | TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF |
| CN112933210A (zh) * | 2019-12-11 | 2021-06-11 | 深圳翰宇药业股份有限公司 | 一种西曲瑞克冻干药物组合物的制备方法 |
Family Cites Families (71)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL36670A (en) | 1971-04-21 | 1974-09-10 | Sela M | Therapeutic basic copolymers of amino acids |
| FR2459619B1 (fr) | 1979-06-26 | 1983-07-29 | Agronomique Inst Nat Rech | Procede pour l'obtention a partir de lactoserum, d'un produit enrichi en alpha-lactalbumine et applications dudit procede |
| US4350156A (en) | 1980-05-29 | 1982-09-21 | Japan Foundation For Artificial Organs | Method and apparatus for on-line filtration removal of macromolecules from a physiological fluid |
| US4455256A (en) | 1981-05-05 | 1984-06-19 | The Regents Of The University Of California | Bone morphogenetic protein |
| DE69427226T2 (de) | 1993-03-24 | 2001-08-30 | Owen Mumford Ltd., Woodstock | Vorrichtung zur injektion |
| US5800808A (en) | 1994-05-24 | 1998-09-01 | Veda Research And Development Co., Ltd. | Copolymer-1 improvements in compositions of copolymers |
| US5631347A (en) | 1995-06-07 | 1997-05-20 | Eli Lilly And Company | Reducing gelation of a fatty acid-acylated protein |
| DE19543737A1 (de) | 1995-11-24 | 1997-05-28 | Hoechst Ag | Verfahren zur Ultrafiltration von Peptide oder Proteine enthaltender biologischer Matrices |
| IL119989A0 (en) | 1997-01-10 | 1997-04-15 | Yeda Res & Dev | Pharmaceutical compositions for oral treatment of multiple sclerosis |
| US6214791B1 (en) | 1997-01-10 | 2001-04-10 | Yeda Research And Development Co. Ltd. | Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1 |
| ES2527760T3 (es) | 1998-07-23 | 2015-01-29 | Yeda Research And Development Co., Ltd. | Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos |
| IL140592A0 (en) | 1998-07-23 | 2002-02-10 | Harvard College | Synthetic peptides and methods of use for autoimmune disease therapies |
| EP1098902A4 (en) | 1998-07-23 | 2002-07-24 | Yeda Res & Dev | TREATMENT OF AUTOIMMUNE DISEASES WITH COPOLYMER 1 AND RELATED COPOLYMERS AND PEPTIDES |
| US6800287B2 (en) | 1998-09-25 | 2004-10-05 | Yeda Research And Development Co., Ltd. | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| HU229720B1 (en) | 1998-09-25 | 2014-05-28 | Yeda Res & Dev | Copolymer 1 related polypeptides for us as molecular weight markers and for therapeutic use |
| US6514938B1 (en) | 1998-09-25 | 2003-02-04 | Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science | Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use |
| AU6281599A (en) | 1998-10-02 | 2000-04-26 | Yeda Research And Development Co. Ltd. | Alternate day administration of copolymer 1 for treating autoimmune diseases |
| EP1128839A4 (en) | 1998-11-12 | 2002-10-09 | Yeda Res & Dev | PHARMACEUTICAL COMPOSITIONS CONTAINING COPOLYMERS OF SYNTHETIC PEPTIDES AND METHODS FOR PREVENTING AND TREATING GVHD AND HVGD |
| US7022663B2 (en) | 2000-02-18 | 2006-04-04 | Yeda Research And Development Co., Ltd. | Oral, nasal and pulmonary dosage formulations of copolymer 1 |
| JP2003522799A (ja) | 2000-02-18 | 2003-07-29 | イエダ・リサーチ・アンド・ディベロップメント・カンパニー・リミテッド・アット・ザ・ウェイズマン・インスティテュート・オブ・サイエンス | コポリマー１の経口、経鼻および経肺投与製剤 |
| US20020077278A1 (en) | 2000-06-05 | 2002-06-20 | Yong V. Wee | Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| IL153236A0 (en) | 2000-06-05 | 2003-07-06 | Teva Pharma | The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders |
| WO2002076503A1 (en) | 2000-06-20 | 2002-10-03 | Mayo Foundation For Medical Education And Research | Treatment of central nervous system diseases by antibodies against glatiramer acetate |
| DE10158009A1 (de) * | 2001-11-21 | 2003-05-28 | Begerow E Gmbh & Co | Verfahren zur Reduzierung der Gesamtkeimzahl in wäßrigen Dispersionen |
| MXPA04005433A (es) | 2001-12-04 | 2004-10-11 | Teva Pharma | Proceso para la medicion de la potencia de acetato de glatiramero. |
| CA2411786C (en) | 2002-11-13 | 2009-01-27 | Brantford Chemicals Inc. | A process for the preparation of polypeptides from n-carboxyanhydrides of amino acids |
| US7777006B2 (en) | 2002-12-31 | 2010-08-17 | Csl Behring L.L.C. | Method for purification of alpha-1-antitrypsin |
| AU2004206120B2 (en) | 2003-01-21 | 2009-09-24 | Yeda Research And Development Co. Ltd. | COP 1 for treatment of inflammatory bowel diseases |
| CA2518079A1 (en) | 2003-03-04 | 2004-10-28 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and alphacalcidol for the treatment of multiple sclerosis |
| ES2466390T3 (es) | 2003-05-14 | 2014-06-10 | Teva Pharmaceutical Industries Limited | Terapia de combinación con acetato de glatiramer y mitoxantrona para el tratamiento de la esclerosis múltiple |
| AU2004280158B2 (en) | 2003-07-18 | 2011-02-17 | Baxter International, Inc. | Methods for fabrication, uses and compositions of small spherical particles prepared by controlled phase separation |
| EP1680087A1 (en) | 2003-10-31 | 2006-07-19 | Teva Pharmaceutical Industries Limited | Nanoparticles for drug delivery |
| WO2005063800A2 (en) | 2003-12-31 | 2005-07-14 | F. Hoffmann-La Roche Ag | Peptide synthesis using decanting filter |
| WO2005084377A2 (en) | 2004-03-03 | 2005-09-15 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and riluzole |
| US7655221B2 (en) | 2004-05-07 | 2010-02-02 | Peptimmune, Inc. | Methods of treating disease with random copolymers |
| US20060194725A1 (en) | 2004-05-07 | 2006-08-31 | James Rasmussen | Methods of treating disease with random copolymers |
| WO2006029036A2 (en) | 2004-09-02 | 2006-03-16 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and n-acetylcysteine for the treatment of multiple sclerosis |
| AU2005282249B2 (en) | 2004-09-09 | 2012-08-02 | Teva Pharmaceutical Industries, Ltd. | Process for preparation of mixtures of polypeptides using purified hydrobromic acid |
| WO2006029411A2 (en) | 2004-09-09 | 2006-03-16 | Yeda Research And Development Co. Ltd. | Mixtures of polypeptides, compositions containing and processes for preparing same, and uses thereof |
| WO2006050122A1 (en) | 2004-10-29 | 2006-05-11 | Sandoz Ag | Processes for preparing glatiramer |
| EP1838326A4 (en) | 2005-02-02 | 2009-09-30 | Teva Pharma | PROCESS FOR PREPARING POLYPEPTIDE MIXTURES BY HYDROGENOLYSIS |
| US20100167983A1 (en) | 2007-10-22 | 2010-07-01 | Teva Pharmaceutical Industries, Ltd. | Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis |
| PT1848415E (pt) | 2005-02-17 | 2013-06-27 | Teva Pharma | Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla |
| US20060240463A1 (en) | 2005-04-25 | 2006-10-26 | Rappaport Family Institute For Research In The Medical Sciences | Markers associated with the therapeutic efficacy of glatiramer acetate |
| WO2007030573A2 (en) | 2005-09-09 | 2007-03-15 | Yeda Research And Development Co. Ltd. | Polypeptides useful for molecular weight determinations |
| WO2007081975A2 (en) | 2006-01-11 | 2007-07-19 | Teva Pharmaceutical Industries, Ltd. | Method of treating multiple sclerosis |
| US20080118553A1 (en) | 2006-06-12 | 2008-05-22 | Anton Frenkel | Tannate salt form of polypeptide mixtures, their preparation and use |
| US20080021192A1 (en) | 2006-07-05 | 2008-01-24 | Momenta Pharmaceuticals, Inc. | Process for the preparation of copolymer-1 |
| CN100569282C (zh) | 2006-10-13 | 2009-12-16 | 俞嘉林 | 注射用骨肽冻干剂及其制备方法 |
| JP2010530975A (ja) | 2007-06-21 | 2010-09-16 | モメンタ ファーマシューティカルズ インコーポレイテッド | コポリマーアッセイ |
| CA2705046C (en) | 2007-07-31 | 2015-03-03 | Natco Pharma Limited | Process for the preparation glatiramer acetate (copolymer-1) |
| BRPI0819001A2 (pt) | 2007-11-28 | 2014-10-07 | Teva Pharma | "método para retardar o acesso de esclerose múltipla clinicamente defenitiva em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão da atividade de doença monitorada por imagem latente de ressonância magnética (mri) em um paciente correndo o risco de desenvolver clinicamente a esclerose múltipla definitiva, método para reduzir a progressão dos sintomas de esclerose múltipla definitiva em um paciente, método para reduzir a freqüência de recidiva em um paciente que experimentou um ataque clínico simples sugestivo de esclerose múltipla e que tem pelo menos uma lesão sugestiva de esclerose múltipla, método para retardar a progressão para a esclerose múltipla clinicamente definitiva em um paciente que apresenta um primeiro evento clínico sugestivo de esclerose múltipla e pelo menos uma lesão sugestiva de esclerose múltipla, uso de acetato de glatiramer e acetato de glatiramer |
| BRPI0912482A2 (pt) | 2008-05-14 | 2020-08-18 | Otonomy, Inc | composições de corticosteróide de liberação controlada e métodos para o tratamento de distúrbios auriculares |
| US8323685B2 (en) | 2008-08-20 | 2012-12-04 | Baxter International Inc. | Methods of processing compositions containing microparticles |
| US20110060279A1 (en) * | 2009-07-15 | 2011-03-10 | Ayelet Altman | Reduced Volume Formulation of Glatiramer Acetate and Methods of Administration |
| US8920373B2 (en) | 2009-07-15 | 2014-12-30 | Teva Pharmaceutical Industries, Ltd. | Reduced volume formulation of glatiramer acetate and methods of administration |
| SG178495A1 (en) | 2009-08-20 | 2012-03-29 | Yeda Res & Dev | Low frequency glatiramer acetate therapy |
| ITMI20092069A1 (it) | 2009-11-25 | 2011-05-26 | Biofer Spa | Metodo per ottenere una miscela di fattori biologici isolati da colostro e miscela di fattori biologici attivi derivata da colostro. |
| US8759302B2 (en) | 2010-03-16 | 2014-06-24 | Teva Pharmaceutical Industries, Ltd. | Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis |
| US8709433B2 (en) | 2010-10-11 | 2014-04-29 | Teva Pharmaceutical Industries Ltd. | Cytokine biomarkers as predictive biomarkers of clinical response for Glatiramer acetate |
| US9029507B2 (en) | 2011-02-14 | 2015-05-12 | Usv Limited | Copolymer-1, process for preparation and analytical methods thereof |
| US8575198B1 (en) * | 2011-09-07 | 2013-11-05 | Momenta Pharmaceuticals, Inc. | In-process control for the manufacture of glatiramer acetate |
| WO2013055683A1 (en) | 2011-10-10 | 2013-04-18 | Teva Pharmaceutical Industries Ltd. | Single nucleotide polymorphisms useful to predict clinical response for glatiramer acetate |
| EP3466964A1 (en) * | 2012-07-06 | 2019-04-10 | 3-D Matrix Ltd. | Fill-finish process for peptide solutions |
| MX2015004563A (es) | 2012-10-10 | 2015-07-14 | Teva Pharma | Biomarcadores predictivos para respuesta clinica para acetato de glatiramero. |
| CA2896957A1 (en) | 2013-01-04 | 2014-07-10 | Teva Pharmaceutical Industries Ltd. | Characterizing a glatiramer acetate related drug product |
| WO2014128079A1 (en) | 2013-02-19 | 2014-08-28 | Synthon B.V. | Glatiramer acetate multidose formulation |
| JP2016512552A (ja) | 2013-03-12 | 2016-04-28 | テバ ファーマシューティカル インダストリーズ リミティド | リツキシマブ導入療法とその後の酢酸グラチラマー療法 |
| CN103169670B (zh) * | 2013-03-22 | 2016-07-06 | 深圳翰宇药业股份有限公司 | 一种醋酸格拉替雷微球及其制备方法 |
| UY35790A (es) | 2013-10-21 | 2015-05-29 | Teva Pharma | Marcadores genéticos que predicen la respuesta al acetato de glatiramer |
| US9155775B1 (en) | 2015-01-28 | 2015-10-13 | Teva Pharmaceutical Industries, Ltd. | Process for manufacturing glatiramer acetate product |
-
2015
- 2015-01-28 US US14/608,126 patent/US9155775B1/en active Active
- 2015-09-21 CA CA2965890A patent/CA2965890A1/en not_active Abandoned
- 2015-09-21 UA UAA201610444A patent/UA116060C2/uk unknown
- 2015-09-21 BR BR112016023736A patent/BR112016023736A2/pt not_active Application Discontinuation
- 2015-09-21 US US15/510,156 patent/US20170312331A1/en not_active Abandoned
- 2015-09-21 PE PE2016001955A patent/PE20170296A1/es unknown
- 2015-09-21 CA CA2945537A patent/CA2945537C/en active Active
- 2015-09-21 RU RU2017104222A patent/RU2669769C2/ru active
- 2015-09-21 JP JP2017534813A patent/JP2018503627A/ja not_active Withdrawn
- 2015-09-21 EA EA201691790A patent/EA028484B1/ru unknown
- 2015-09-21 KR KR1020177012458A patent/KR102268210B1/ko active Active
- 2015-09-21 EP EP15880609.1A patent/EP3113785A4/en not_active Withdrawn
- 2015-09-21 WO PCT/US2015/051203 patent/WO2016122722A1/en not_active Ceased
- 2015-09-21 KR KR1020167028604A patent/KR101737295B1/ko active Active
- 2015-09-21 US US14/860,053 patent/US9763993B2/en active Active
- 2015-09-21 CN CN201580071551.XA patent/CN107530394B/zh active Active
- 2015-09-21 MX MX2016011219A patent/MX352734B/es active IP Right Grant
- 2015-09-21 AU AU2015380381A patent/AU2015380381B2/en active Active
- 2015-09-24 RS RS20170439A patent/RS55959B1/sr unknown
- 2015-09-24 EP EP17162112.1A patent/EP3238706A1/en not_active Withdrawn
- 2015-09-24 LT LTEP15186721.5T patent/LT3050556T/lt unknown
- 2015-09-24 SM SM20170227T patent/SMT201700227T1/it unknown
- 2015-09-24 ME MEP-2017-103A patent/ME02721B/me unknown
- 2015-09-24 EP EP15186721.5A patent/EP3050556B1/en not_active Revoked
- 2015-09-24 ES ES15186721.5T patent/ES2584190T3/es active Active
- 2015-09-24 DK DK15186721.5T patent/DK3050556T3/en active
- 2015-09-24 PT PT151867215T patent/PT3050556T/pt unknown
- 2015-09-24 SI SI201530058A patent/SI3050556T1/sl unknown
- 2015-09-24 PL PL15186721T patent/PL3050556T3/pl unknown
- 2015-09-24 HU HUE15186721A patent/HUE034059T2/en unknown
- 2015-09-25 EA EA201791555A patent/EA201791555A3/ru unknown
- 2015-09-25 EA EA201500881A patent/EA028811B1/ru unknown
- 2015-09-25 AR ARP150103103A patent/AR102096A1/es not_active Application Discontinuation
-
2016
- 2016-08-16 AU AU2016101453A patent/AU2016101453B4/en not_active Expired
- 2016-09-15 IL IL247851A patent/IL247851A0/en unknown
- 2016-10-07 ZA ZA2016/06903A patent/ZA201606903B/en unknown
- 2016-10-13 CL CL2016002607A patent/CL2016002607A1/es unknown
- 2016-12-14 AU AU2016273881A patent/AU2016273881A1/en not_active Abandoned
-
2017
- 2017-03-28 US US15/471,765 patent/US20170196930A1/en not_active Abandoned
- 2017-04-13 CY CY20171100442T patent/CY1118826T1/el unknown
- 2017-04-21 HR HRP20170625TT patent/HRP20170625T1/hr unknown
- 2017-09-18 US US15/707,378 patent/US20180000884A1/en not_active Abandoned
- 2017-10-19 US US15/788,698 patent/US20180036363A1/en not_active Abandoned
-
2018
- 2018-01-23 AU AU2018200518A patent/AU2018200518A1/en not_active Abandoned
- 2018-07-17 JP JP2018134124A patent/JP6592150B2/ja active Active
-
2019
- 2019-06-06 IL IL267152A patent/IL267152A/en unknown
-
2020
- 2020-09-24 IL IL277601A patent/IL277601B/en unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2016011219A (es) | Procedimiento para fabricar un producto de acetato de glatiramer. | |
| ZA202102906B (en) | Liquid protein formulations containing viscosity-lowering agents | |
| EP4600271A3 (en) | Bioactive molecule conjugate, preparation method and use thereof | |
| WO2015095624A3 (en) | Drug mixing and delivery system and method | |
| SG10201902915VA (en) | Polysaccharide and nucleic acid formulations containing viscosity-lowering agents | |
| MY188825A (en) | High-concentration monoclonal antibody formulations | |
| WO2015165413A8 (zh) | 一种新型的稳定型抗体药物耦联物及其制备方法和用途 | |
| EA201690207A1 (ru) | Композиция традиционной китайской медицины и препарат из нее и их применение | |
| EA201691918A1 (ru) | Фармацевтические составы ингибитора киназ семейства raf, способы их получения и способы их применения | |
| TN2017000011A1 (en) | Aqueous formulation comprising paracetamol and ibuprofen. | |
| SA517390475B1 (ar) | نظام أكياس متعددة وطريقة لتحضير مكونات الدم | |
| WO2016100949A3 (en) | Method and compositions for dissolving or solubilizing therapeutic agents | |
| HK1217633A1 (zh) | 冻乾方法 | |
| BR112018008769A2 (pt) | formulações farmacêuticas, formulações líquidas aquosa reconstituída e liofilizada, seringa, método de fabricação de uma formulação farmacêutica, método para tratamento de uma doença e uso de uma formulação reconstruída | |
| PH12017501828A1 (en) | Stabilized pharmaceutical composition and method for preparing same | |
| MX379568B (es) | Productos para el suministro de compuestos de diagnóstico/terapeuticos al corazon. | |
| EP4474012A3 (en) | Melatonin mini-tablets and method of manufacturing the same | |
| WO2014075119A3 (de) | Vorrichtung und verfahren zur herstellung, dosierung und verpackung von arzneimitteln | |
| EA201600331A1 (ru) | Фармацевтическая композиция в форме раствора для внутривенного и внутримышечного введения и способ ее получения | |
| Bianchi | DRESS syndrome: case report | |
| EA201500385A1 (ru) | Способ получения интерферона бета 1-альфа и фармацевтическая композиция, содержащая интерферон бета 1-альфа | |
| IN2014MU01178A (es) | ||
| HK1224578A1 (en) | Drug mixing and delivery system and method | |
| TH155343A (th) | องค์ประกอบเชิงเภสัชกรรมของเบนโซไดอะซีพีน (benzodiazepine) แบบใช้ทางในจมูก | |
| EA201400452A1 (ru) | Способ получения противоопухолевого препарата на основе доцетаксела |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |